Jin Rong Jie·2025-08-05 11:48Core Viewpoint - Junshi Biosciences-U's stock price has shown an upward trend, reflecting positive market sentiment towards its innovative drug development and commercialization efforts [1] Company Overview - Junshi Biosciences-U's latest stock price is 39.46 yuan, up by 1.80 yuan from the previous trading day, with a trading volume of 196,000 hands and a transaction amount of 755 million yuan [1] - The company specializes in the research and commercialization of innovative drugs, with its core product being the first domestically approved PD-1 monoclonal antibody, Toripalimab injection, which has received approval for 12 indications, 10 of which are included in the national medical insurance catalog [1] - The company has established a diverse research and development system covering monoclonal antibodies, bispecific antibodies, and ADCs, with R&D centers located in the US, Shanghai, and Suzhou [1] Financial Activities - Recently, the company raised over 1 billion Hong Kong dollars through a rights issue, with 70% of the funds allocated for innovative drug research and development, including PD-1/VEGF bispecific antibodies and EGFR/HER3 bispecific ADCs [1] - In the first quarter of 2025, the total number of license-out transactions for innovative drugs in China reached 41, with a total value of 36.929 billion US dollars [1] Market Position - Junshi Biosciences-U has established a global commercialization network covering over 80 countries and regions, utilizing various models such as licensing and joint ventures to advance its international strategy [1] - As of August 5, 2025, the net inflow of main funds into Junshi Biosciences-U was 45.8254 million yuan, accounting for 0.15% of its circulating market value, while the cumulative net outflow over the past five trading days was 126 million yuan, representing 0.42% of its circulating market value [1]